ZA200501837B - Inhibitors of fatty aced amide hydrolase - Google Patents
Inhibitors of fatty aced amide hydrolase Download PDFInfo
- Publication number
- ZA200501837B ZA200501837B ZA200501837A ZA200501837A ZA200501837B ZA 200501837 B ZA200501837 B ZA 200501837B ZA 200501837 A ZA200501837 A ZA 200501837A ZA 200501837 A ZA200501837 A ZA 200501837A ZA 200501837 B ZA200501837 B ZA 200501837B
- Authority
- ZA
- South Africa
- Prior art keywords
- subunit
- group
- mmol
- fatty acid
- acid amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41724702P | 2002-10-08 | 2002-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200501837B true ZA200501837B (en) | 2006-06-28 |
Family
ID=32093990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200501837A ZA200501837B (en) | 2002-10-08 | 2005-03-03 | Inhibitors of fatty aced amide hydrolase |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7662971B2 (enExample) |
| EP (2) | EP1549624B1 (enExample) |
| JP (1) | JP4628789B2 (enExample) |
| KR (1) | KR20050070041A (enExample) |
| CN (1) | CN1703407A (enExample) |
| AT (1) | ATE431342T1 (enExample) |
| AU (1) | AU2003275493A1 (enExample) |
| BR (1) | BR0314980A (enExample) |
| CA (1) | CA2501575A1 (enExample) |
| DE (1) | DE60327640D1 (enExample) |
| EA (1) | EA008767B1 (enExample) |
| ES (1) | ES2325686T3 (enExample) |
| MX (1) | MXPA05003762A (enExample) |
| WO (1) | WO2004033652A2 (enExample) |
| ZA (1) | ZA200501837B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| DE60327640D1 (enExample) | 2002-10-08 | 2009-06-25 | Scripps Research Inst | |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| DE102004039326A1 (de) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| PL2937341T3 (pl) | 2004-12-30 | 2017-11-30 | Janssen Pharmaceutica N.V. | Pochodne fenyloamidowe kwasu 4-(benzylo)-piperazyno-1-karboksylowego oraz związki powiązane, jako modulatory hydrolazy amidu kwasu tłuszczowego (FAAH) do leczenia lęku, bólu i innych schorzeń |
| PE20070099A1 (es) | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| US20090111778A1 (en) | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
| WO2007098142A2 (en) | 2006-02-17 | 2007-08-30 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
| WO2008013963A2 (en) | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| WO2008030532A2 (en) * | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
| AU2008257154B2 (en) * | 2007-05-25 | 2014-03-06 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| EP2161997A4 (en) * | 2007-05-31 | 2011-04-06 | Scripps Research Inst | TRICYCLIC INHIBITORS OF FATTY ACID AMIDHYDROLASE |
| EP2254415B1 (en) | 2008-02-19 | 2013-01-23 | Janssen Pharmaceutica, N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| US20110184026A1 (en) * | 2008-06-19 | 2011-07-28 | Boger Dale L | C4-substituted alpha-keto oxazoles |
| US8987312B2 (en) | 2008-07-09 | 2015-03-24 | The Scripps Research Institute | Alpha-keto heterocycles as FAAH inhibitors |
| US8673941B2 (en) | 2008-08-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
| WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| AU2009330821B2 (en) * | 2008-12-24 | 2015-06-11 | Bial - Portela & Ca, S.A. | Pharmaceutical compounds |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| AU2010293429B2 (en) | 2009-09-09 | 2015-12-17 | Sumitomo Dainippon Pharma Co., Ltd. | 8-oxodihydropurine derivative |
| CN102647984B (zh) | 2009-10-02 | 2015-03-25 | 埃维克辛公司 | 抗炎症的2-羰基噻唑和2-羰基恶唑 |
| US20120225097A1 (en) | 2009-11-12 | 2012-09-06 | Hawryluk Natalie A | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| KR20120123691A (ko) * | 2010-01-28 | 2012-11-09 | 머크 샤프 앤드 돔 코포레이션 | 통증 및 기타의 적응증의 치료를 위한 제약 조성물 |
| WO2011112828A1 (en) | 2010-03-12 | 2011-09-15 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| WO2011133444A1 (en) | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| BR112013004585B1 (pt) * | 2010-09-20 | 2021-09-08 | Merck Sharp & Dohme Corp | Lipídeo catiônico, composição de lnp, e, uso de um lipídeo catiônico |
| CN102964311B (zh) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | 一种合成4-甲基-5-烷氧基噁唑的方法 |
| ES2648188T3 (es) * | 2012-02-17 | 2017-12-29 | Epitech Group S.P.A. | Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias |
| US20150376161A1 (en) | 2013-01-29 | 2015-12-31 | Avexxin As | Antiiflammatory and antitumor 2-oxothiazoles abd 2-oxothiophenes compounds |
| NZ719916A (en) | 2013-11-01 | 2017-09-29 | Merial Inc | Antiparasitic and pesticidal isoxazoline compounds |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| WO2016160168A1 (en) * | 2015-02-20 | 2016-10-06 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| RU2017134509A (ru) | 2015-04-24 | 2019-04-04 | Омерос Корпорейшн | Ингибиторы pde10 и соответствующие композиции и способы |
| EP3095787A1 (en) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| JP7531351B2 (ja) | 2019-11-13 | 2024-08-09 | 東京エレクトロン株式会社 | 基板処理方法、基板処理装置、および基板処理システム |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA19269A1 (fr) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | Perfectionnement relatif a des derives de n-arylbenzamides . |
| US5821371A (en) * | 1994-10-24 | 1998-10-13 | Eli Lilly And Comany | Heterocyclic compounds and their preparation and use |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020103192A1 (en) * | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| DE60327640D1 (enExample) | 2002-10-08 | 2009-06-25 | Scripps Research Inst |
-
2003
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
- 2003-10-08 EA EA200500633A patent/EA008767B1/ru unknown
- 2003-10-08 AT AT03759771T patent/ATE431342T1/de not_active IP Right Cessation
- 2003-10-08 EP EP03759771A patent/EP1549624B1/en not_active Expired - Lifetime
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/zh active Pending
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en not_active Ceased
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
- 2003-10-08 EP EP09006391A patent/EP2093220A3/en not_active Withdrawn
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
- 2003-10-08 ES ES03759771T patent/ES2325686T3/es not_active Expired - Lifetime
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/ja not_active Expired - Fee Related
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/pt not_active IP Right Cessation
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/ko not_active Withdrawn
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/es not_active Application Discontinuation
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2093220A3 (en) | 2009-11-11 |
| EA008767B1 (ru) | 2007-08-31 |
| EP1549624B1 (en) | 2009-05-13 |
| KR20050070041A (ko) | 2005-07-05 |
| CA2501575A1 (en) | 2004-04-22 |
| WO2004033652A2 (en) | 2004-04-22 |
| EA200500633A1 (ru) | 2005-10-27 |
| JP2006502229A (ja) | 2006-01-19 |
| EP2093220A2 (en) | 2009-08-26 |
| EP1549624A2 (en) | 2005-07-06 |
| MXPA05003762A (es) | 2005-07-22 |
| ES2325686T3 (es) | 2009-09-14 |
| JP4628789B2 (ja) | 2011-02-09 |
| EP1549624A4 (en) | 2006-09-20 |
| BR0314980A (pt) | 2005-08-09 |
| AU2003275493A1 (en) | 2004-05-04 |
| US20060111359A1 (en) | 2006-05-25 |
| DE60327640D1 (enExample) | 2009-06-25 |
| US7662971B2 (en) | 2010-02-16 |
| ATE431342T1 (de) | 2009-05-15 |
| CN1703407A (zh) | 2005-11-30 |
| WO2004033652A3 (en) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1549624B1 (en) | Inhibitors of fatty acid amide hydrolase | |
| Brown et al. | The chemistry of pseudomonic acid. 18. Heterocyclic replacement of the α, β-unsaturated ester: synthesis, molecular modeling, and antibacterial activity | |
| JP4931893B2 (ja) | Ｐｐａｒ活性化化合物及びこれを含有する医薬組成物 | |
| Malamas et al. | New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties | |
| JP5301286B2 (ja) | Ｆｘ受容体を調節するための化合物及び方法 | |
| AU2007301607A1 (en) | Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | |
| CA2696232C (en) | Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof | |
| JPWO2007119887A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JP2006516254A (ja) | Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体 | |
| KR20010085340A (ko) | ｈＰＰＡＲγ 및 ｈＰＰＡＲα 활성제로서의 치환된옥사졸 및 티아졸 유도체 | |
| CA2322162A1 (en) | Inhibitors of phospholipase enzymes | |
| JP2012526783A (ja) | シクロペンタ［ｃ］ピロール−２−カルボン酸エステル誘導体、これらの調製およびこれらの治療用途 | |
| EP2262782A1 (en) | Novel aminomethyl benzene derivatives | |
| Thore et al. | Docking, synthesis, and pharmacological investigation of novel substituted thiazole derivatives as non-carboxylic, anti-inflammatory, and analgesic agents | |
| JPWO2008016175A1 (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 | |
| Wu et al. | Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors | |
| WO2015160772A1 (en) | Tetrahydro-benzoimidazolyl modulators of tgr5 | |
| CN1930152A (zh) | 用于治疗i.a.肥胖症和糖尿病的1,3－二噁烷衍生物及其类似物 | |
| ZA200304913B (en) | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient. | |
| JP2013538808A (ja) | Ｄｇａｔ１阻害剤としての複素環式化合物 | |
| Shibata et al. | Synthesis and Structure–Activity Relationships of Novel Zwitterionic Compounds as Peroxisome Proliferator Activated Receptor α/γ Dual Agonists with Improved Physicochemical Properties | |
| Baashen | Synthesis of N, N'-diacylhydrazines and their use in various synthetic transformations | |
| WO2016017699A1 (ja) | アゾールカルボン酸誘導体 | |
| Stump et al. | Synthesis of 2, 4, 5-trisubstituted thiazoles with a 5-(N, N-dimethylaminomethyl) substituent |